HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity
Diabetes is a common condition with a dismal prognosis. According to the International Diabetes Federation, 537 million people worldwide have diabetes. Cardiovascular disorders (CVD) are the major cause of death globally. Diabetes mellitus type 2 (T2DM) increases the risk of CVD. Since 2008, the FDA...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Indian Heart Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0019483222003765 |
| _version_ | 1797893856493043712 |
|---|---|
| author | P.P. Mohanan Pankaj Jariwala |
| author_facet | P.P. Mohanan Pankaj Jariwala |
| author_sort | P.P. Mohanan |
| collection | DOAJ |
| description | Diabetes is a common condition with a dismal prognosis. According to the International Diabetes Federation, 537 million people worldwide have diabetes. Cardiovascular disorders (CVD) are the major cause of death globally. Diabetes mellitus type 2 (T2DM) increases the risk of CVD. Since 2008, the FDA has required all new antihyperglycemic treatments to show no increased CV risk. Years of glucocentric diabetic therapy have left many patients on medicines with no known CV benefit. GLP-1 receptor agonists (GLP-1RAs) are excellent glucose-lowering medicines with little risk of hypoglycaemia, CVD and weight loss.GLP-1RAs may also delay renal disease development. As an adjunct to metformin or ongoing therapy, GLP1RAs or sodium-glucose cotransporter-2 inhibitors are recommended by the American Diabetes Association and the European Association for the Study of Diabetes (EASD). Thus, this review summarises GLP-1RA and their significance in the paradigm shift in diabetes care recommendations from glucocentric to gluco-cardiocentric. |
| first_indexed | 2024-04-10T06:59:37Z |
| format | Article |
| id | doaj.art-8ec4560c68eb4614a5866877754a90eb |
| institution | Directory Open Access Journal |
| issn | 0019-4832 |
| language | English |
| last_indexed | 2024-04-10T06:59:37Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Indian Heart Journal |
| spelling | doaj.art-8ec4560c68eb4614a5866877754a90eb2023-02-28T04:08:13ZengElsevierIndian Heart Journal0019-48322023-01-0175118HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio CentricityP.P. Mohanan0Pankaj Jariwala1Department of Cardiology, Westfort Hi-Tech Hospital, Ltd., Thrissur, IndiaDepartment of Cardiology, Yashoda Hospitals, Somajiguda, Raj Bhavan Road, Hyderabad, 500 082, Telangana, India; Corresponding author. Department of Cardiology & Cardiothoracic Surgery, Yashoda Hospitals, Somajiguda, Raj Bhavan Road, Hyderabad, 500 082, Telangana, India.Diabetes is a common condition with a dismal prognosis. According to the International Diabetes Federation, 537 million people worldwide have diabetes. Cardiovascular disorders (CVD) are the major cause of death globally. Diabetes mellitus type 2 (T2DM) increases the risk of CVD. Since 2008, the FDA has required all new antihyperglycemic treatments to show no increased CV risk. Years of glucocentric diabetic therapy have left many patients on medicines with no known CV benefit. GLP-1 receptor agonists (GLP-1RAs) are excellent glucose-lowering medicines with little risk of hypoglycaemia, CVD and weight loss.GLP-1RAs may also delay renal disease development. As an adjunct to metformin or ongoing therapy, GLP1RAs or sodium-glucose cotransporter-2 inhibitors are recommended by the American Diabetes Association and the European Association for the Study of Diabetes (EASD). Thus, this review summarises GLP-1RA and their significance in the paradigm shift in diabetes care recommendations from glucocentric to gluco-cardiocentric.http://www.sciencedirect.com/science/article/pii/S0019483222003765T2DMASCVDGLP-1RAsGuidelines |
| spellingShingle | P.P. Mohanan Pankaj Jariwala HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity Indian Heart Journal T2DM ASCVD GLP-1RAs Guidelines |
| title | HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity |
| title_full | HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity |
| title_fullStr | HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity |
| title_full_unstemmed | HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity |
| title_short | HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity |
| title_sort | how did glp 1ras bring about a paradigm shift in the guidelines of managing t2dm a path to gluco cardio centricity |
| topic | T2DM ASCVD GLP-1RAs Guidelines |
| url | http://www.sciencedirect.com/science/article/pii/S0019483222003765 |
| work_keys_str_mv | AT ppmohanan howdidglp1rasbringaboutaparadigmshiftintheguidelinesofmanagingt2dmapathtoglucocardiocentricity AT pankajjariwala howdidglp1rasbringaboutaparadigmshiftintheguidelinesofmanagingt2dmapathtoglucocardiocentricity |